Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Lingang Laboratory, Shanghai 200031, China.
J Med Chem. 2024 Feb 22;67(4):2837-2848. doi: 10.1021/acs.jmedchem.3c01891. Epub 2024 Feb 1.
The pyrazolopyrimidine (PP) heterocycle is a versatile and widely deployed core scaffold for the development of kinase inhibitors. Typically, a 4-amino-substituted pyrazolopyrimidine binds in the ATP-binding pocket in a conformation analogous to the 6-aminopurine of ATP. Here, we report the discovery of ZNL0325 which exhibits a flipped binding mode where the C3 position is oriented toward the ribose binding pocket. ZNL0325 and its analogues feature an acrylamide side chain at the C3 position which is capable of forming a covalent bond with multiple kinases that possess a cysteine at the αD-1 position including BTK, EGFR, BLK, and JAK3. These findings suggest that the ability to form a covalent bond can override the preferred noncovalent binding conformation of the heterocyclic core and provides an opportunity to create structurally distinct covalent kinase inhibitors.
吡唑并嘧啶(PP)杂环是开发激酶抑制剂的多功能且广泛应用的核心支架。通常,4-氨基取代的吡唑并嘧啶以类似于 ATP 中 6-氨基嘌呤的构象结合在 ATP 结合口袋中。在这里,我们报告了 ZNL0325 的发现,它表现出翻转的结合模式,其中 C3 位置朝向核糖结合口袋。ZNL0325 及其类似物在 C3 位置具有丙烯酰胺侧链,能够与多个具有αD-1 位置半胱氨酸的激酶形成共价键,包括 BTK、EGFR、BLK 和 JAK3。这些发现表明形成共价键的能力可以克服杂环核心的首选非共价结合构象,并为创建结构独特的共价激酶抑制剂提供了机会。